Purpose:
mRCC, P., Cancer
METASTATIC RENAL CELL CARCINOMA, CANCER
Current address for P. Iruku: Cone Health Cancer Center, Greensboro, North Carolina; and current address for M. Amirault, Massachusetts General Hospital, Boston, Massachusetts.
Immune checkpoint inhibitor and VEGFR inhibitor combinations are effective treatments for patients with metastatic renal cell carcinoma (mRCC). This phase I/II clinical trial evaluated the safety and efficacy of pembrolizumab and cabozantinib in patients with mRCC.